EUVIMEDEUVIMED entdecken
Crossref

Approach to the Patient With Nonalcoholic Fatty Liver Disease

Renata Belfort-DeAguiar iD, Romina Lomonaco, Kenneth Cusi iD

The Journal of Clinical Endocrinology & Metabolism · 2023

DOI: 10.1210/clinem/dgac624 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2023. Verfasst von Renata Belfort-DeAguiar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Department, Endocrinology Section, Yale University, New Haven, Connecticut 06520, USA. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 128 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Nonalcoholic fatty liver disease (NAFLD) is associated with obesity and type 2 diabetes (T2D), causing substantial burden from hepatic and extrahepatic complications. However, endocrinologists often follow people who are at the highest risk of its more severe form with nonalcoholic steatohepatitis or NASH (i.e., T2D or obesity with cardiometabolic risk factors). Endocrinologists are in a unique position to prevent cirrhosis in this population with early diagnosis and treatment.

Objective

This work aims to offer endocrinologists a practical approach for the management of patients with NAFLD, including diagnosis, fibrosis risk stratification, and referral to hepatologists. Patients (1) An asymptomatic patient with obesity and cardiometabolic risk factors, found to have hepatic steatosis; (2) a patient with T2D and NASH with clinically significant liver fibrosis; and (3) a liver transplant recipient with a history of NASH cirrhosis, with significant weight regain and with recurrent NAFLD on the transplanted organ.

Conclusion

NASH can be reversed with proper management of obesity and of T2D. While no agents are currently approved for the treatment of NASH, treatment should include lifestyle changes and a broader use of structured weight-loss programs, obesity pharmacotherapy, and bariatric surgery. Diabetes medications such as pioglitazone and some glucagon-like peptide 1 receptor agonists may also improve liver histology and cardiometabolic health. Sodium-glucose cotransporter-2 inhibitors and insulin may ameliorate steatosis, but their effect on steatohepatitis remains unclear. Awareness by endocrinologists about, establishing an early diagnosis of fibrosis (ie, FIB-4, liver elastography) in patients at high-risk of cirrhosis, long-term monitoring, and timely referral to the hepatologist are all critical to curve the looming epidemic of cirrhosis from NAFLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseDiabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsHumansLiverLiver CirrhosisObesity

Stichwörter der Autor:innen

NAFLDNASHcirrhosisinsulin resistanceliver fatnonalcoholic steatohepatitissteatosistype 2 diabetes

Substanzen

Sodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Internal Medicine Department, Endocrinology Section, Yale University, New Haven, Connecticut 06520, USA.
  • Division of Endocrinology, Diabetes and Metabolism, University of Florida, Gainesville, Florida 32610, USA.

ORCID-Profile: Renata Belfort-DeAguiar, Kenneth Cusi

Zitieren

APA

Belfort-DeAguiar, R., Lomonaco, R., & Cusi, K. (2023). Approach to the Patient With Nonalcoholic Fatty Liver Disease. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgac624

Vancouver

Belfort-DeAguiar R, Lomonaco R, Cusi K. Approach to the Patient With Nonalcoholic Fatty Liver Disease. The Journal of Clinical Endocrinology & Metabolism. 2023. doi:10.1210/clinem/dgac624

BibTeX
@article{BelfortDeAguiar2023,
  author = {Belfort-DeAguiar, Renata and Lomonaco, Romina and Cusi, Kenneth},
  title = {Approach to the Patient With Nonalcoholic Fatty Liver Disease},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2023},
  doi = {10.1210/clinem/dgac624}
}
Kostenlos starten →